My favorite points from the EC: 1. Buy back plan of shares. This strengthens our current SP, and it is placing another layer of defence against future short activity. 2. Bancel saying that he is not interested to expand Moderna's pipeline to include small molecules. He said Moderna loves information molecules too much that they would just want to focus on it. They are not yet planning to play it safe. No diversification to non-mrna modality, they are going all out on this one. GL.$Moderna, Inc.(MRNA)$
精彩评论